JP2015507175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015507175A5 JP2015507175A5 JP2014544870A JP2014544870A JP2015507175A5 JP 2015507175 A5 JP2015507175 A5 JP 2015507175A5 JP 2014544870 A JP2014544870 A JP 2014544870A JP 2014544870 A JP2014544870 A JP 2014544870A JP 2015507175 A5 JP2015507175 A5 JP 2015507175A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer cells
- prostate specific
- prostate
- steap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629886P | 2011-11-29 | 2011-11-29 | |
| US61/629,886 | 2011-11-29 | ||
| US201261703099P | 2012-09-19 | 2012-09-19 | |
| US61/703,099 | 2012-09-19 | ||
| PCT/US2012/066998 WO2013082249A2 (en) | 2011-11-29 | 2012-11-29 | Compositions and methods for prostate cancer analysis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015507175A JP2015507175A (ja) | 2015-03-05 |
| JP2015507175A5 true JP2015507175A5 (enExample) | 2016-01-28 |
| JP6219304B2 JP6219304B2 (ja) | 2017-10-25 |
Family
ID=47324459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544870A Active JP6219304B2 (ja) | 2011-11-29 | 2012-11-29 | 前立腺癌分析のための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130143237A1 (enExample) |
| EP (1) | EP2786151B1 (enExample) |
| JP (1) | JP6219304B2 (enExample) |
| KR (1) | KR101951514B1 (enExample) |
| CN (1) | CN104067127A (enExample) |
| AR (1) | AR089028A1 (enExample) |
| AU (1) | AU2012345926A1 (enExample) |
| BR (1) | BR112014012882A2 (enExample) |
| CA (1) | CA2854042A1 (enExample) |
| IL (1) | IL232466A (enExample) |
| MX (1) | MX350807B (enExample) |
| RU (1) | RU2641968C2 (enExample) |
| SG (1) | SG11201402711SA (enExample) |
| WO (1) | WO2013082249A2 (enExample) |
| ZA (1) | ZA201403110B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2530505B2 (ja) | 1990-03-20 | 1996-09-04 | 三ツ星ベルト株式会社 | 自着層付き防水シ―トの製造法 |
| CN105646661A (zh) * | 2014-03-24 | 2016-06-08 | 朱育盼 | 特异性结合前列腺癌的短肽pcp2及其应用 |
| JP6815331B2 (ja) * | 2015-04-21 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| AU2018247767B2 (en) | 2017-04-03 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to STEAP-1 |
| CN108179134B (zh) * | 2017-12-27 | 2020-11-24 | 武汉大学 | 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用 |
| US11530274B2 (en) | 2018-07-02 | 2022-12-20 | Amgen Inc. | Anti-STEAP1 antigen-binding protein |
| WO2021046331A1 (en) * | 2019-09-05 | 2021-03-11 | Memorial Sloan Kettering Cancer Center | Anti-steap1 antibodies and uses thereof |
| BR102020013625A2 (pt) * | 2020-07-02 | 2022-01-11 | Universidade Federal de Uberlândia | Aptâmero modificado, sistema aptaimunológico, painel aptaimunológico, kit, método e uso no diagnóstico de câncer de próstata |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5597531A (en) | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5698271A (en) | 1989-08-22 | 1997-12-16 | Immunivest Corporation | Methods for the manufacture of magnetically responsive particles |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| BR9907852A (pt) | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
| US6200765B1 (en) * | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
| EP2080802B1 (en) | 1998-06-01 | 2017-03-29 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| IL129299A0 (en) * | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| EP1360496A4 (en) | 2001-02-16 | 2005-03-09 | Immunivest Corp | METHOD AND REAGENTS FOR THE QUICK AND EFFICIENT INSULATION OF CIRCULATING CANCER CELLS |
| US20030190602A1 (en) | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| CA2563735C (en) * | 2004-04-22 | 2020-07-14 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP2061814B1 (en) * | 2006-10-27 | 2012-06-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| JP2010508855A (ja) * | 2006-11-08 | 2010-03-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| US8445225B2 (en) * | 2008-09-05 | 2013-05-21 | The Scripps Research Institute | Methods for the detection of circulating tumor cells |
| EP2558109A4 (en) | 2010-04-16 | 2014-09-24 | Bellicum Pharmaceuticals Inc | METHOD FOR TREATING HARD TUMORS |
-
2012
- 2012-11-29 US US13/689,407 patent/US20130143237A1/en not_active Abandoned
- 2012-11-29 RU RU2014126358A patent/RU2641968C2/ru not_active IP Right Cessation
- 2012-11-29 AR ARP120104485A patent/AR089028A1/es unknown
- 2012-11-29 WO PCT/US2012/066998 patent/WO2013082249A2/en not_active Ceased
- 2012-11-29 AU AU2012345926A patent/AU2012345926A1/en not_active Abandoned
- 2012-11-29 CA CA2854042A patent/CA2854042A1/en not_active Abandoned
- 2012-11-29 CN CN201280067510.XA patent/CN104067127A/zh active Pending
- 2012-11-29 BR BR112014012882A patent/BR112014012882A2/pt not_active Application Discontinuation
- 2012-11-29 SG SG11201402711SA patent/SG11201402711SA/en unknown
- 2012-11-29 KR KR1020147017563A patent/KR101951514B1/ko active Active
- 2012-11-29 MX MX2014006187A patent/MX350807B/es active IP Right Grant
- 2012-11-29 EP EP12798559.6A patent/EP2786151B1/en active Active
- 2012-11-29 JP JP2014544870A patent/JP6219304B2/ja active Active
-
2014
- 2014-04-29 ZA ZA2014/03110A patent/ZA201403110B/en unknown
- 2014-05-05 IL IL232466A patent/IL232466A/en not_active IP Right Cessation
-
2015
- 2015-10-21 US US14/919,388 patent/US9632091B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015507175A5 (enExample) | ||
| Campos-Silva et al. | High sensitivity detection of extracellular vesicles immune-captured from urine by conventional flow cytometry | |
| Balitzer et al. | Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria | |
| Lee et al. | Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC) | |
| Soh et al. | CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab | |
| RU2646498C2 (ru) | Способы детектирования 5Т4-положительных циркулирующих опухолевых клеток и способы диагностики 5Т4-положительного рака у млекопитающего | |
| RU2014126358A (ru) | Композиции и способы анализа рака предстательной железы | |
| Fathi et al. | Detection of CD133-marked cancer stem cells by surface plasmon resonance: its application in leukemia patients | |
| JP7022191B2 (ja) | 前立腺がんの分析のための組成物及び方法 | |
| HRP20160461T1 (hr) | Solubilna humana st-2 antitijela i eseji | |
| JP2017518366A5 (enExample) | ||
| JP2015502547A5 (enExample) | ||
| Blank et al. | Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors | |
| Alston et al. | Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ? | |
| Choi | Pericardial malignant mesothelioma diagnosed in a dog by immunocytochemistry of the pericardial fluid: a case report | |
| Forster et al. | Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells | |
| Huang et al. | Concurrent detection of cellular and molecular cancer markers using an immunomagnetic flow system | |
| Kadota et al. | Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma | |
| CN111886498A (zh) | 试剂盒、测定试剂盒及测定方法 | |
| Shea et al. | Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status | |
| JP2018520366A5 (enExample) | ||
| Liu et al. | Evaluation of acridine orange florescence in exfoliative urinary cytology for diagnosing bladder carcinoma | |
| JP2016504590A5 (enExample) | ||
| US20170328900A1 (en) | Methods and materials for capture antibody targeted fluorescent in-situ hybridization (cat-fish) | |
| JP2017505911A5 (enExample) |